Nonadrenergic imidazoline binding sites on human platelets.
Human platelets are shown to possess at least two high-affinity, imidazol(in)e-preferring binding sites that are pharmacologically distinct from alpha-2 adrenoceptors. These nonadrenergic sites were radiolabeled even in the presence of a 10 microM norepinephrine mask of alpha-2 adrenoceptors. Heterogeneity at the nonadrenergic sites was demonstrated by comparing [3H]idazoxan (IDX) binding vs. [125I]p-iodoclonidine (PIC) binding. Nonadrenergic [125I]PIC-labeled sites were enriched in platelet plasma membranes, whereas the nonadrenergic sites labeled by [3H] IDX were codistributed between plasma and internal membranes (nonadrenergic [125I]PIC-labeled sites had Bmax = 62 fmol/mg in plasma membranes and 20 fmol/mg in internal membranes vs. the [3H]IDX-labeled sites had Bmax = 141 fmol/mg in plasma membranes and 192 fmol/mg in internal membranes). Furthermore, competition binding studies in the presence of a 10 microM norepinephrine mask revealed major (approximately 75%) and minor (approximately 25%) binding components on plasma membranes for [125I]PIC. Affinities for the major nonadrenergic [125I]PIC binding site were highly comparable to human subtype-I1 imidazol(in)e receptor sites in the brain stem (rank order: moxonidine > clonidine > cirazoline > IDX > amiloride). However, the minor component of [125I]PIC binding was similar to a site reported in kidney, having low affinities for all compounds tested, except guanabenz. Finally, a third nonadrenergic internal membrane site, labeled by [3H]IDX, was consistent with a subtype-I2 imidazol(in)e receptor site (rank order: cirazoline > IDX >> amiloride > moxonidine > clonidine). Thus, based on differential subcellular distributions and affinity constants, human platelets appear to possess imidazoline receptors (subtype-I1 imidazol(in)e receptor and subtype-I2 imidazol(in)e receptor), plus a novel guanabenz-sensitive site, as well as an alpha-2A adrenoceptor. These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to clonidine and endogenous clonidine-displacing substance(s), and may serve as markers of imidazoline receptors in humans.
Piletz
J E
JE
Department of Psychiatry, Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio.
Sletten
K
K
D000345:Affinity Labels / Q000378:metabolism; D001665:Binding Sites; D001667:Binding, Competitive; D001792:Blood Platelets / Q000378:metabolism / Q000648:ultrastructure*; D002462:Cell Membrane / Q000187:drug effects / Q000648:ultrastructure; D003000:Clonidine / Q000031:analogs & derivatives / Q000378:metabolism; D004146:Dioxanes / Q000378:metabolism; D006801:Humans; D019329:Idazoxan; D054755:Imidazoline Receptors; D007457:Iodine Radioisotopes; D007700:Kinetics; D009638:Norepinephrine / Q000494:pharmacology; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism; D011955:Receptors, Drug / Q000378:metabolism*; D014316:Tritium
D000345:Affinity Labels; D004146:Dioxanes; D054755:Imidazoline Receptors; D007457:Iodine Radioisotopes; D018341:Receptors, Adrenergic, alpha-2; D011955:Receptors, Drug; D014316:Tritium; C053113:4-iodoclonidine; D003000:Clonidine; D009638:Norepinephrine; D019329:Idazoxan